Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer

Daniel C. McFarland, Krzysztof J. Misiukiewicz

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations


Recent Phase III data presented at the American Society of Clinical Oncology (ASCO)2013 annual conference by Brose et al led to the US Food and Drug Administration (FDA) approval of sorafenib for the treatment of well-differentiated radioactive iodine-resistant metastatic thyroid cancer. This is the second drug in40 years to be FDA approved for this indication. Recent reviews and a meta-analysis reveal a modest ability to induce a partial remission but substantial ability to halt disease progression. Given the significant activating mutations present in thyroid cancer, many of which are inhibited by sorafenib, the next logical approach may be to combine targeted rational therapies if permitted by collective toxicity profiles. This systematic review aims to summarize the recent Phase II/III data leading to the FDA approval of sorafenib for radioactive iodine therapy differentiated thyroid cancer and highlights recent novel combination therapy trials.

Original languageEnglish
Pages (from-to)1291-1299
Number of pages9
JournalOncoTargets and Therapy
StatePublished - 15 Jul 2014


  • Novel thyroid cancer treatment
  • Targeted therapy
  • Tyrosine kinase inhibitors


Dive into the research topics of 'Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer'. Together they form a unique fingerprint.

Cite this